Content area
Full Text
Jubilant DraxImage Inc., a wholly owned subsidiary of Jubilant Pharma Ltd, announced that the U.S. Food and Drug Administration has approved Ruby-Fill, an innovative technology for Positron Emission Tomography (PET) myocardial perfusion imaging (MPI).
Comprised of a Rubidium-82 (Rb-82) generator and precedent setting elution system, Ruby-Fill is used to produce a personalized patient dose of Rubidium Rb 82 chloride used to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease (CAD), which is an important component of diagnosing CAD.
"We are proud to bring to the U.S. market a groundbreaking, state-of-the-art technology for myocardial perfusion imaging. Ruby-Fill expands DraxImage's nuclear medicine portfolio and is a part of our commitment to provide healthcare providers and their patients with innovative health...